When Merck & Co. pulled Vioxx from pharmacy shelves worldwide on 30 September 2004, chief executive Raymond Gilmartin framed it as a responsible company acting on new data; the documented record shows a five-year gap between that posture and what the company’s own clinicians had measured. Vioxx (rofecoxib), a COX-2 selective anti-inflammatory approved by the U.S. Food and Drug Administration on 20 May 1999 and marketed as a gentler painkiller that spared the stomach, was instead associated with one of the largest drug-safety catastrophes in regulatory history. FDA drug-safety reviewer David Graham would testify to the Senate Finance Committee on 18 November 2004 that the drug had caused on the order of 88,000 to 139,000 excess heart attacks and strokes in the United States, of which perhaps 30 to 40 percent were fatal — a toll he compared to between two and four jumbo-jet crashes a week sustained over five years.
The gap between promise and reality was not discovered late; it was visible in Merck’s own trials. The VIGOR study, published in The New England Journal of Medicine on 23 November 2000 under lead author Claire Bombardier, showed that the 8,076 patients taking rofecoxib had roughly four to five times the rate of myocardial infarction of patients taking the older drug naproxen — a relative risk the published paper reported as 0.2 in naproxen’s favor. Merck attributed the difference to a supposed protective effect of naproxen rather than a cardiac hazard of Vioxx — a hypothesis that was never proven and that the company continued to advance while sales climbed past $2.5 billion a year and a sales force of more than 3,000 representatives carried the message to prescribers.
The withdrawal came only when the harm became impossible to explain away. The APPROVe trial — designed to test whether Vioxx prevented recurrent colon polyps, not to study the heart — was halted early on 23 September 2004 after showing that rofecoxib roughly doubled the risk of confirmed cardiovascular events after eighteen months of use, against placebo. The verdict here is therefore plain at the outset: an approved, heavily advertised, trusted medicine reached tens of millions of patients while the signal that would eventually condemn it sat in the company’s data, the FDA’s review files, and the medical literature, fully legible to anyone with access and the will to read it.
What followed was the largest pharmaceutical mass-tort reckoning of its era. In November 2007 Merck agreed to pay $4.85 billion to resolve roughly 27,000 lawsuits covering some 47,000 plaintiff groups, NEJM issued a formal “Expression of Concern” alleging the VIGOR authors had withheld cardiac data, and the case became the standard byword for how surrogate-endpoint approval, aggressive marketing, and suppressed safety signals can converge into mass harm before any regulator pulls the cord.
When the U.S. Food and Drug Administration asked American Home Products to pull fenfluramine (Pondimin) and dexfenfluramine (Redux) from the market on 15 September 1997, it ended a weight-loss phenomenon that had been built on an off-label pairing the agency had never approved and a long-term safety record nobody had assembled. Fen-Phen — the colloquial yoking of fenfluramine, a serotonin-releasing anorectic approved in 1973, with phentermine, a stimulant approved in 1959 — had become, by 1996, one of the most prescribed drug ideas in America: roughly 18 million prescriptions in that year alone and an estimated 6 million users, exposure on the order of 61 million patient-months. The gap between the promise of easy, doctor-blessed thinness and the harm was a class of damage that does not announce itself: scarred heart valves and, more rarely, lethal pulmonary hypertension.
The combination’s popularity rested on a 1992 study and on a regulatory permission slip that was never granted. The FDA had approved fenfluramine and phentermine each as standalone short-term anorectics; it had never approved their combination, nor either drug for the open-ended, cosmetic, multi-year use that fen-phen clinics dispensed. The 1996 approval of dexfenfluramine — the more potent right-handed isomer, sold as Redux and the first new prescription weight-loss drug in 23 years — poured accelerant on the market, despite an FDA advisory committee that had initially voted against it and known pulmonary-hypertension concerns in European data.
The verdict is plain at the outset. A combination the agency never sanctioned, marketed for a use it never authorized, reached millions before any long-term cardiac safety study existed; the damage was found not by the regulator or the manufacturer but by Mayo Clinic cardiologists who noticed a pattern. Their report, published in the New England Journal of Medicine on 28 August 1997, described 24 women with no prior cardiac history who had developed an unusual valvular disease — leaflets thickened with a glistening, carcinoid-like plaque — after taking fen-phen. The drug came off the market eighteen days later.
What followed was, for its era, the largest product-liability reckoning in pharmaceutical history. American Home Products (renamed Wyeth in 2002) agreed to a $3.75 billion national class settlement in 1999, then watched its total liability climb past $21 billion as tens of thousands of plaintiffs opted out, and the case became the standard byword for what happens when an off-label combination and a direct-to-consumer obesity market outrun the safety science that should have preceded them.
When Pfizer pulled Bextra from the U.S. market on 7 April 2005 — not voluntarily, but at the written request of the U.S. Food and Drug Administration — the company described a balanced judgment about risks and benefits; the documented record shows a drug whose dangers had been measurable for at least a year and whose marketing had outrun every safety signal it generated. Bextra (valdecoxib), a COX-2 selective anti-inflammatory developed by G. D. Searle/Pharmacia and co-promoted by Pfizer after approval on 20 November 2001 for osteoarthritis, rheumatoid arthritis, and menstrual pain, was withdrawn for two converging harms: an excess of heart attacks and strokes, and a rare but lethal class of skin reactions. The FDA concluded the drug offered no demonstrated advantage over existing NSAIDs to justify either.
The cardiovascular signal was not theoretical. A randomized trial in 1,671 cardiac-surgery patients — Nussmeier et al., published in The New England Journal of Medicine on 17 March 2005 — found that patients given parecoxib followed by valdecoxib after coronary-artery-bypass-graft surgery suffered cardiovascular events at a risk ratio of 3.7 (95% confidence interval 1.0–13.5; P=0.03), roughly 2.0 percent versus 0.5 percent on placebo. This was the same COX-2 hazard that had condemned Vioxx six months earlier, surfacing in Pfizer’s own franchise.
The dermatologic harm was, if anything, more distinctive. Because valdecoxib is a sulfonamide, it carried a strong association with Stevens-Johnson syndrome and toxic epidermal necrolysis — conditions in which the skin blisters and sloughs and which kill a meaningful fraction of those who develop them. By the end of March 2004 the FDA had logged on the order of 63 reported cases of SJS/TEN tied to the drug, several of them fatal. In mid-October 2004, Pfizer sent physicians a warning letter; a boxed warning followed; the withdrawal followed that. The verdict is therefore plain at the outset: a me-too painkiller with no proven edge over cheap generics was kept on the market and aggressively promoted while it accumulated both a cardiac body count and a roster of fatal skin reactions — and the reckoning, when it came, took the form of the largest health-care fraud prosecution the Justice Department had ever brought.
When Abbott Laboratories agreed on 8 October 2010 to pull Meridia (sibutramine) from the U.S. market at the request of the Food and Drug Administration, the company maintained that the drug remained safe for its approved population; the documented record shows that the very trial regulators had ordered Abbott to run had measured the opposite, and had measured it in the patients most likely to receive a weight-loss prescription. Sibutramine, a serotonin–norepinephrine reuptake inhibitor approved by the FDA in November 1997 as an appetite suppressant for obese patients, was instead found to raise the risk of nonfatal heart attack and stroke by roughly 16 percent while delivering a placebo-adjusted weight loss of only about 2.5 percent of body weight after five years.
The gap between promise and harm was not a late surprise; it was the product of a contradiction visible at approval. Sibutramine worked by raising levels of norepinephrine and serotonin to blunt appetite, and that same sympathetic activation predictably raised blood pressure and heart rate. A drug marketed to obese patients — a group already loaded with cardiovascular risk — carried a mechanism that pushed the cardiovascular system in exactly the wrong direction. The FDA approved it anyway on a surrogate endpoint, pounds lost on a scale, and deferred the question of whether those pounds came at the cost of hearts.
The answer arrived in the Sibutramine Cardiovascular Outcomes Trial, or SCOUT, a roughly 10,744-patient study that European regulators had demanded as a post-marketing condition. After a mean of 3.4 years of follow-up, the primary composite outcome — nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest, and cardiovascular death — occurred in 11.4 percent of the sibutramine group versus 10.0 percent of placebo (hazard ratio 1.16; p=0.015). The verdict is therefore plain at the outset: a drug whose central trade-off was legible from its pharmacology in 1997 was permitted to circulate for thirteen years until the safety trial its makers were compelled to conduct confirmed the harm.
What followed was a coordinated transatlantic revocation rather than a courtroom reckoning. The European Medicines Agency suspended sibutramine on 21 January 2010; the FDA recommended against its use and accepted Abbott’s voluntary withdrawal that October. Sibutramine became the byword for a specific failure mode in obesity medicine: approving a drug on a weight surrogate when its own mechanism telegraphs a cardiovascular hazard, then waiting a decade-plus for a mandated outcomes trial to state the obvious.
When the U.S. Food and Drug Administration announced on 29 March 2007 that the makers of pergolide had agreed to pull the drug from the American market, the action was filed as a routine post-market safety measure; the documented record shows that the fibrotic heart-valve mechanism that condemned Permax had been understood, in chemical detail, for years before the echocardiograms were read. Pergolide (marketed by Eli Lilly as Permax and approved by the FDA in 1988 as an adjunct to levodopa for Parkinson’s disease) was an ergot-derived dopamine agonist that relieved tremor and rigidity by stimulating dopamine receptors — but it also bound potently to the 5-HT2B serotonin receptor on heart-valve tissue, the identical target that had driven the valvulopathy behind the 1997 fen-phen catastrophe.
The gap between promise and harm was not an unforeseeable side effect. Two studies published side by side in The New England Journal of Medicine on 4 January 2007 closed the case. René Schade and colleagues, mining the U.K. General Practice Research Database cohort of 11,417 patients, found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation. Renzo Zanettini’s echocardiographic study found clinically important (moderate-to-severe) regurgitation in 23.4 percent of pergolide patients versus 5.6 percent of controls — and, decisively, 0 percent in patients on non-ergot dopamine agonists, which do not hit the 5-HT2B receptor.
The verdict is therefore plain at the outset: a drug with no proven efficacy advantage over safer, mechanistically distinct alternatives kept hundreds of thousands of Parkinson’s patients exposed to a known fibrotic hazard years after the signal was legible. The FDA asked Lilly to add valvulopathy to the warnings section in 2003 and mandated a boxed warning in 2006; neither step removed the drug. Only the 2007 NEJM pair forced a withdrawal the pharmacology had argued for since at least 2002 — a quieter case than the blockbuster scandals, with no settlement fund and no Senate hearing, only a back-of-the-shelf agent kept in front-line use long after a receptor profile shared with a recalled diet drug had told clinicians exactly where to look.